On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


DGE’s 3rd Risk Based Quality Management Summit to Integrate Quality into Clinical Trials and Ensure Effective Monitoring

Clinical research executives, data management specialists, and industry experts, are all invited to attend the 3rd Risk Based Quality Management Summit that will be held from April 25-26, 2023 at the Le Méridien, in Philadelphia. The summit will be focused on conferring the details of executing data flow process maps, data monitoring tools, audit trails, and quality tolerance limits.

RBQM is now being embraced to address the significant increase in research duration, cost, and complexity of clinical research. The newest version of the Good Clinical Practice (“GCP”) quality standard extends the RBM approach to every facet of study execution, implementing the principles to all parts of quality management needing effective centralized monitoring systems and processes.

The 3rd Annual RBQM Summit will provide real-world lessons from businesses on the leading edge of execution and promote RBQM. This two-day event will feature plenary keynotes from biopharma thought leaders, focused on explicit functions and issues within clin ops, as well as research enterprise and innovation, with interactive and informal breakout discussion groups and networking.

Featured Topics and Discussions:

  • Nurture a culture of efficiency and ensure end-to-end quality, cost management, and reliability
  • Improve monitoring to include remote data monitoring, site and central monitoring
  • Refine skills for risk identification, response, and mitigation
  • Ensure the efficiency of QTLs and KRIs
  • Ways to respond to central monitoring outputs

A risk-based approach to clinical trials helps to decrease trial costs and complexity while maximizing the R&D budget. The best practices in RBQM influence decentralized trials and clinical study methodology, focusing on risk-based data review including central and site monitoring.

The 3rd Risk Based Quality Management Summit is designed to help you establish cross-functional risk-management teams to manage your clinical trials, decreasing risks and improving drug development. Attendees will get access to valuable information on relevant matters in the risk-based management and monitoring space. Attendees can make the most of this engagement opportunity featuring live sessions, downloadable resources, and Q&A sessions.

Register today and hear the experts share advanced approaches and best practices to optimize data quality and improve risk management and trial efficiency.

To learn more, please visit https://ibn.fm/FYN

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.